ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares of Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock in a transaction dated Thursday, July 9th. The stock was purchased at an average price of $1.74 per share, with a total value of $261,000.00. Following the completion of the purchase, the chief executive officer owned 300,000 shares in the company, valued at $522,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Boer Daniel Anton De also recently made the following trade(s):

• On Tuesday, July 7th, Boer Daniel Anton De purchased 150,000 shares of ProQR Therapeutics stock. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $238,500.00.

ProQR Therapeutics Stock Performance

Shares of ProQR Therapeutics stock opened at $1.70 on Tuesday. ProQR Therapeutics N.V. has a 52 week low of $1.33 and a 52 week high of $3.10. The stock has a 50 day moving average price of $1.62 and a two-hundred day moving average price of $1.67. The stock has a market capitalization of $179.11 million, a PE ratio of -3.40 and a beta of 0.04.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The company had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.19 million. Research analysts forecast that ProQR Therapeutics N.V. will post -0.52 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on PRQR shares. Wall Street Zen downgraded shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Chardan Capital decreased their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Weiss Ratings lowered shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Finally, JonesTrading lowered their target price on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aberdeen Group plc lifted its position in shares of ProQR Therapeutics by 28.4% during the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock worth $5,960,000 after buying an additional 651,853 shares in the last quarter. Ikarian Capital LLC grew its holdings in shares of ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after acquiring an additional 600,000 shares in the last quarter. Privium Fund Management B.V. increased its position in shares of ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after acquiring an additional 359,475 shares during the last quarter. Citadel Advisors LLC increased its position in shares of ProQR Therapeutics by 73.2% during the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 277,749 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in ProQR Therapeutics by 80.8% during the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock worth $879,000 after acquiring an additional 194,369 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.